The best second-line therapy in patients with wild-type KRAS metastatic colorectal cancer was investigated in terms of drug choice, duration of therapy, and efficacy of subsequent therapy in patients treated with first-line FOLFIRI plus either cetuximab (arm A) or bevacizumab (arm B) in the FIRE-3 trial. Second-line therapy was given for a median of 5.0 months for patients in arm A versus 3.2 months for those in arm B. Both overall and progression-free survival after initiation of second-line treatment were longer in patients in arm A than those in arm B. In this patient population, first-line anti-EGFR therapy might enable more-effective subsequent treatment, including responses to antiangiogenic agents.
References
Modest, D. P. et al. Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J. Clin. Oncol. 10.1200/JCO.2015.61.2887
Rights and permissions
About this article
Cite this article
Sequence of drugs—more important than drug exposure?. Nat Rev Clin Oncol 12, 562 (2015). https://doi.org/10.1038/nrclinonc.2015.149
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.149